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A B S T R A C T
Background
Commercially available preparations of garlic have been reported to have beneficial effects on some of the risk factors associated with
atherosclerosis.
Objectives
To assess the effects of garlic (both dried and non-powdered preparations) for the treatment of peripheral arterial occlusive disease.
Search methods
We searched the Cochrane Peripheral Vascular Diseases Group trials register, the Central Register of Controlled Trials (CENTRAL) in
The Cochrane Library, Issue 4, 2007, AMED, EMBASE, Science Citation Index, abstracts of relevant symposia and reference lists of
relevant articles up to November 2007. We also contacted pharmaceutical companies, investigators and experts in garlic therapies.
Selection criteria
Randomised trials of garlic therapy in patients with lower limb atherosclerosis were included. The main outcomes were objective
measures of progression of underlying atherosclerosis (e.g. ankle pressure measurements, treadmill testing) and subjective measures (e.g.
symptom progression).
Data collection and analysis
Two review authors (RJ and JK) independently extracted data and assessed trial quality. One author (RJ) contacted investigators to
obtain information needed for the review that could not be found in published reports.
Main results
One eligible trial with 78 participants was found. Both men and women (aged 40 to 75) were included. The follow-up period was
short, 12 weeks only.
After twelve weeks of treatment, pain-free walking distance increased from 161 to 207 metres in the group receiving garlic and from
172 to 203 metres in the placebo group. This was not a statistically significant difference. There was no difference in change of systolic
or diastolic blood pressure, heart rate, ankle and brachial pressures. No severe side effects were observed and nine patients taking garlic
(28%) and four patients taking placebo (12%) complained of a noticeable garlic smell.
One further trial was excluded from the review because it did not include any clinical measurements.
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Authors’ conclusions
One small trial of short duration found no statistically significant effect of garlic on walking distance.
P L A I N L A N G U A G E S U M M A R Y
Garlic for peripheral arterial occlusive disease affecting the legs
The most common symptom of peripheral arterial occlusive disease is intermittent claudication, discomfort in the legs that is triggered
by exercise and relieved with rest. The underlying cause is atherosclerosis. Risk factors associated with the development of peripheral
arterial disease include cigarette smoking, raised blood cholesterol and other fats (lipids), high blood pressure and diabetes. Garlic has
been used as a medicinal therapy since ancient times. The main active ingredient is an unstable odorous sulphurous compound called
allicin so that active ingredients may be lost in processing, and with different types of preparation. Commercially available preparations
of garlic are reported to have beneficial effects on some of the risk factors for vascular disease. With fresh garlic, at least seven cloves of
garlic per day are needed. Apart from the odour, garlic has only minor gastrointestinal side effects.
The review authors made a thorough search of the medical literature and found one controlled trial in which 78 participants with
peripheral arterial occlusive disease were randomized to receive garlic or a placebo medication. The dose of garlic was two coated tablets
of 200 mg oral standardised garlic powder twice daily. Both men and women, aged 40 to 75 years, were included although sixteen did
not keep to their treatment.
After twelve weeks of treatment, pain-free walking distance increased similarly whether receiving garlic or placebo. Similarly there was
no difference in the changes in blood pressure, heart rate and pressure differences between the ankle and brachial pressures. No severe
side effects were observed although more people taking garlic (28%) than placebo (12%) complained of a noticeable garlic smell.
Peripheral arterial occlusive disease is a long-term (chronic) condition and any improvements in symptoms would require longer-term
treatment and follow up than in this study.
B A C K G R O U N D
Peripheral arterial occlusive disease primarily affects the major ar-
teries of the lower limb. The most common symptom in early oc-
clusive disease is intermittent claudication - discomfort in the legs
induced by exercise and relieved by rest. Numerous risk factors
have been associated with the development of peripheral arterial
disease, including cigarette smoking, raised blood lipids, hyper-
tension and diabetes.
The medicinal use of garlic can be traced back to Egyptian times.
The primary active component of garlic is an unstable odorous sul-
phurous compound called allicin. Meta-analysis of commercially
available preparations of garlic have been reported to have benefi-
cial effects on some of the risk factors associated with atheroscle-
rosis such as serum cholesterol (Silagy 1994; Warshafsky 1993).
With fresh garlic, the dosages needed to inhibit platelet aggrega-
tion or lower cholesterol levels are unacceptably high; at least seven
cloves of garlic per day (Kleijnen 1989).
Garlic is an acceptable therapy to the general population and, apart
from the odour, has only minor gastrointestinal side effects. Tri-
als with endpoints more meaningful and relevant than laboratory
endpoints, however, are necessary before claiming that garlic im-
proves health. Many trials have been carried out to assess its effi-
cacy in the treatment and risk reduction of coronary atherosclero-
sis, but few trials have been carried out in people with peripheral
vascular disease.
The purpose of this review is to assess the efficacy of garlic therapy
in improving the morbidity associated with peripheral arterial oc-
clusive disease. The relevant trials of garlic have been considered.
As one of the difficulties in showing the effectiveness of garlic is
that active ingredients may be lost in processing, the type of prepa-
ration (i.e. fresh, powdered or non-powdered) has been taken into
consideration.
O B J E C T I V E S
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Toestablish the effectiveness of garlic in the treatment of peripheral
arterial occlusive diseases.
We wished to test the following hypotheses:
a)That commercially prepared garlic preparations have a beneficial
effect on themorbidity associatedwith peripheral arterial occlusive
disease;
b) That the magnitude of the effects observed with dried garlic
is greater than with non-powder preparations in the treatment of
peripheral arterial occlusive disease.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We assessed randomised controlled trials of garlic versus placebo
for the treatment of peripheral arterial occlusive disease. As there
are currently only a few trials in this area, any trials identified in
future that either use alternation (e.g. allocation by date of birth or
days of the week) or that have not been analysed on an intention-
to-treat basis (as long as all randomised patients were accounted
for) will be included. Blinding of participants is a particular prob-
lem in garlic trials because of its characteristic smell.
Types of participants
People with peripheral arterial occlusive disease were included.
Most participants had intermittent claudication (diagnosed either
by questionnaire or clinically), but those with critical limb is-
chaemia and asymptomatic disease identified by testing (angiog-
raphy, ankle pressures, etc.) were also eligible.
People with aortic disease and no peripheral arterial disease were
excluded.
Types of interventions
Any trial of garlic therapy for the treatment of peripheral arterial
occlusive disease was considered. Since one of the difficulties in
showing the effectiveness of garlic is that active ingredients may
be lost in processing, the type of preparation (i.e. fresh, powdered
or non-powdered) was taken into consideration.
Types of outcome measures
Two main outcome measures were considered: objective mea-
sures of progression of underlying atherosclerosis (e.g. ankle pres-
sure measurements, treadmill testing, angiography); and subjec-
tive measures (e.g. symptom progression).
Search methods for identification of studies
We searched the trials register of the Cochrane Peripheral Vascular
Diseases (PVD) Review Group (last searched 8 November 2007)
and the Cochrane Central Register of Controlled Trials CEN-
TRAL in The Cochrane Library, (last searched Issue 4, 2007) for
reports of randomised controlled trials of garlic for the treatment
of lower limb atherosclerosis. We used the search strategy devel-
oped by the Cochrane PVD Group to search these databases.
The trials register of the PVD Group has been constructed
from regular electronic searches of MEDLINE (January 1966
to date), EMBASE (January 1980 to date), and through hand-
searching relevant journals and conference proceedings. The full
list of journals that have been handsearched, as well as the
search strategies for the electronic databases are described in the
’Search strategies for the identification of studies’ section within
the editorial information about the Cochrane PVD Group in
The Cochrane Library (http://www.mrw.interscience.wiley.com/
cochrane/clabout/articles/PVD/frame.html).See Appendix 1 for
the strategy used to search CENTRAL.
Additional search strategies used to identify studies included:
searches of AMED (Allied and Alternative Medicine Database),
EMBASE and ISI WoS Science Citation Index using the terms
’garlic’ and (’peripheral arterial occlusive disease’ or ’intermittent
claudicat*’ or ’lower limb atherosclerosis’); direct contact with
principal investigators of trials; searching abstracts of relevant sym-
posia as published in journals and through colleagues who at-
tended; handsearching of other relevant medical journals; contact
with experts in garlic therapies; direct contact with pharmaceuti-
cal companies listed as manufacturing garlic; cross referencing the
bibliographies of identified trials. The most recent searches were
carried out in November 2007.
Data collection and analysis
Selection of trials
Ruth Jepson selected trials for possible inclusion in the review and
sought additional information from the principal investigators of
all trials.
Assessment of methodological quality
Ruth Jepson and Jos Kleijnen independently assessed the method-
ological quality of trials using a standard scoring sheet developed
by the Cochrane PVD Review Group. Any discrepancies were
considered by Gill Leng until a consensus decision could be made.
Data extraction
For the one included trial, information was collected about the
method of randomisation, blinding and whether an intention-to-
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treat analysis could possibly be done. Ruth Jepson and Jos Kleij-
nen extracted data independently to ensure quality control. Self-
designed forms were used for the data extraction in accordance
with Cochrane guidelines.
Statistical analysis
If more trials become available in the future, the heterogeneity
between trial results will be tested. Such tests will be subjective, by
clinical judgement of differences in patient populations, interven-
tions and outcome assessments, and objective, using appropriate
statistical tests. Depending on the results of the heterogeneity as-
sessments, part of the outcomes may be pooled statistically using
relevant techniques.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Only one trial (Keisewetter 1993) was identified that fulfilled the
criteria for inclusion in the review. Summary details of this trial are
given in the ’Characteristics of included studies’ table. The trial
was relatively small with only 80 patients being randomised and
16 of these did not show sufficient compliance. The duration of
the trial was 12 weeks. Further details were requested from the
principal author, but no reply was received.
One further trial (Koscielny 1999) was excluded because it only
measured arteriosclerotic effects and not clinical symptoms. In
addition, the subject population was described as ’probationers’,
and it was not clear if these were healthy volunteers or people with
pre-existing disease.
Risk of bias in included studies
The one included study (Keisewetter 1993) was randomised, dou-
ble-blinded and placebo-controlled. There was no mention of the
methodof randomisation, nor the concealment of allocation (score
B). Inclusion and exclusion criteria were adequate, but the trial was
of short duration (only 12 weeks). No intention-to-treat analysis
was used for the sixteen patients who did not complete the study.
Effects of interventions
The weighted mean difference and a fixed-effect model were used
to test the significance of the results. The mean difference between
the two groups at the end of treatment was analysed rather than
the mean change within the two groups before and after treat-
ment. After twelve weeks of treatment, pain-free walking distance
increased from 161 to 207 metres in the garlic group and from
172 to 203 metres in the placebo group. There was no difference
in change of systolic or diastolic blood pressure, heart rate, ankle
and brachial pressures. No severe side effects were observed but
nine patients taking garlic (28%) and four patients taking placebo
complained of a noticeable garlic smell (12%). No studies were
found comparing dried garlic with non-powder preparations.
D I S C U S S I O N
The only included study was small and of short duration (12
weeks). Although no statistically significant improvement was
found overall, the authors of the trial report that there was a sig-
nificant increase in walking distance, but this only occurred in
the last weeks of therapy. Peripheral arterial occlusive disease is a
chronic condition, and any subjective or objective improvement
in outcomes would require longer term therapy and follow up.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
One small trial of short duration found no statistically significant
effect on walking distance. Thus, at this stage, garlic as a therapy
for the treatment of peripheral arterial occlusive disease cannot be
recommended.
Implications for research
Further trials of garlic therapy for the treatment of peripheral ar-
terial occlusive disease are required to determine its effectiveness.
These trials should be large and of reasonable duration.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Keisewetter 1993
Methods Study design: Randomised, placebo controlled, double-blind single centre trial
Method of randomisation: not stated.
Exclusions post-randomisation: Not stated.
Losses to follow up: 8 patients in each group (out of a total of 78 patients)
Participants Participants: men and women aged 40 to 75 years.
Country: Germany.
Inclusion criteria: femoral and/or tibial type PAOD; angiographically-localised stenosis or occlusion of the
superficial femoral artery free vascular system of the popliteal artery (stenosis under 60% was excluded);
mean stable PFWD between 80 and 300 metres; Doppler pressure values over peripheral arteries at rest
greater than 50 mm Hg, and haematocrit values up to 47%
Exclusion criteria: arterial occlusion of the pelvic type in the lower extremities (or stenosis over 60%)
; endangiitis obliterans; nonvascular walking impediment; operations within the preceding 3 months;
history of a cerebral infarctionwith gait disturbances; severe cerebral insufficiency; polyneuropathy; cardiac
infarction within the past 6 weeks; unstable angina pectoris, crescendo angina, angina CCS stage III;
cardiac insufficiency stage II or IV; haemodynamically relevant valvular heart defect*; arrhythmia Lown
IVb and V; higher degree SA and AV blocks; heart rate at rest below 50 per min or over 100 per min;
chronic venous insufficiency; inadequately compensated severe internal diseases; cerebral spasms; intake of
anticoagulants, rheological or vasoactive drugs, analgesics and antiphlogistic intake not discontinued for
at least 4 weeks prior to the study; readjustment or correction of therapy with cardiac glycosides, diuretics,
antidiabetics, antiarrhythmics, calcium antagonists; Doppler pressure values over peripheral arteries below
50 mm Hg
Interventions Treatment: 2 x 2 coated tablets of 200 mg oral standardised garlic powder (Kwai, Sapec)
Control: Placebo tablets.
Duration of trial: 12 weeks.
Outcomes Primary: PFWD.
Secondary: Diastolic blood pressure, cholesterol concentrations, rheological parameters, side effects
Notes Original article states ’hemodynamically relevant valvular nearby defect’
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
PAOD: peripheral arterial occlusive disease
PFWD: pain-free walking distance
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Koscielny 1999 Only measured anti-atherosclerotic effects such as plaque volume. Did not include any clinical measurements such
as walking distances. Also, not clear who the study population was (only described as ’probationers’)
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D A T A A N D A N A L Y S E S
Comparison 1. Garlic versus placebo




participants Statistical method Effect size
1 Pain-free walking distance 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
Analysis 1.1. Comparison 1 Garlic versus placebo, Outcome 1 Pain-free walking distance.
Review: Garlic for peripheral arterial occlusive disease
Comparison: 1 Garlic versus placebo
Outcome: 1 Pain-free walking distance
Study or subgroup garlic placebo Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Keisewetter 1993 32 207.1 (85) 32 203.1 (72.8) 4.00 [ -34.78, 42.78 ]
-100 -50 0 50 100
garlic placebo
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
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#1 MeSH descriptor Intermittent Claudication explode all trees
#2 intermitt* near claudic*
#3 peripher* near arter* near occlus*
#4 critic* near limb* near isch*
#5 (#1 OR #2 OR #3 OR #4)
#6 MeSH descriptor Garlic explode all trees
#7 MeSH descriptor Allium explode all trees
#8 garlic*
#9 allium*
#10 (#6 OR #7 OR #8 OR #9)
#11 (#5 AND #10)
WH A T ’ S N E W
Last assessed as up-to-date: 7 November 2007.
Date Event Description
12 May 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 2, 1996
Review first published: Issue 3, 1997
Date Event Description
14 November 2007 New search has been performed No new trials found. Conclusions remain unchanged.
21 November 2006 New search has been performed Added Plain Language Summary. No new trials found.
11 July 2005 New search has been performed No new trials found. Review updated without change.
26 May 2004 New search has been performed Review updated without change. No new studies found.
4 April 2003 New search has been performed One new study excluded, no change to conclusions.
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C O N T R I B U T I O N S O F A U T H O R S
Ruth Jepson: selected trials for inclusion; sought additional information from the principal investigators of all trials; assessed trials for
quality; extracted data; wrote text; revised review (April 2003).
Jos Kleijnen: assessed trials for quality; extracted data.
Gillian Leng: resolved disagreements between RJ and JK regarding trial quality.
The Peripheral Vascular Diseases Review Group assisted with searching for trials for this review.
D E C L A R A T I O N S O F I N T E R E S T
None.
S O U R C E S O F S U P P O R T
Internal sources
• The University of Edinburgh, UK.
External sources
• Chief Scientist Office, Scottish Government Health Directorates, The Scottish Government, UK.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Phytotherapy; ∗Plants, Medicinal; Arterial Occlusive Diseases [∗drug therapy]; Garlic [∗therapeutic use]
MeSH check words
Female; Humans; Male
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